Merck & Co., Inc.

As of October 31, 2025, Merck & Co., Inc. shows a mildly bullish trend based on weekly indicators, despite mixed signals from monthly charts and underperformance compared to the S&P 500.

As of October 31, 2025, Merck & Co., Inc. shows a mildly bullish trend with daily moving averages and weekly KST supporting this outlook, despite underperforming the S&P 500 year-to-date and over the past year.

As of October 31, 2025, Merck & Co., Inc. shows a mildly bullish trend supported by weekly indicators, though it has underperformed against the S&P 500 with year-to-date and one-year returns of -13.57% and -15.97%, respectively.

As of October 17, 2025, Merck & Co., Inc. is considered undervalued with a P/E ratio of 15 compared to the peer average of 26.1, a strong growth potential indicated by a PEG ratio of 0.03, and a competitive EV to EBITDA ratio of 11.50, despite recent stock underperformance and a robust ROE of 40.02% and dividend yield of 5.70%.

As of October 17, 2025, Merck & Co., Inc. is considered undervalued with a favorable valuation grade, showing strong fundamentals like a P/E ratio of 15, a PEG ratio of 0.03, and a dividend yield of 5.70%, despite a year-to-date stock performance lagging behind the S&P 500.

As of October 3, 2025, Merck & Co., Inc. shows a mildly bearish trend overall, with mixed technical indicators, having outperformed the S&P 500 recently but significantly underperformed over the year-to-date and one-year periods.

As of October 3, 2025, Merck & Co., Inc. shows a mildly bearish trend, with daily moving averages indicating bearishness and underperformance against the S&P 500, returning -19.05% over the year compared to the S&P's 17.82%.

As of October 3, 2025, Merck & Co., Inc. has a mildly bearish trend, with daily moving averages indicating bearishness, while weekly indicators show mild bullishness, and it has underperformed the S&P 500 year-to-date with a return of -10.34% compared to the S&P's 14.18%.

As of August 1, 2025, Merck & Co., Inc. has shifted to a mildly bearish trend, with daily moving averages indicating bearishness, while monthly indicators remain bearish and the stock has underperformed the S&P 500 with a year-to-date return of -18.04%.

As of July 7, 2025, Merck & Co., Inc. is considered undervalued with an attractive valuation grade, supported by favorable P/E and PEG ratios, a strong dividend yield, and high ROE, despite recent stock performance lagging behind the S&P 500.

As of June 18, 2025, Merck & Co., Inc. shows a mildly bearish trend, with daily moving averages and Bollinger Bands indicating bearishness, while mixed signals from MACD and KST suggest a cautious approach.

As of April 24, 2025, Merck & Co., Inc. is considered fairly valued with a P/E ratio of 15, an EV to EBITDA of 11.50, a PEG ratio of 0.03, a dividend yield of 5.70%, and has underperformed the S&P 500 with a return of -38.68% over the past year, making it attractive compared to peers like Eli Lilly and Johnson & Johnson.

As of March 2022, Merck & Co., Inc.'s management team includes Kenneth Frazier as Chairman, President, and CEO, and Leslie Brun as Lead Independent Director, along with independent directors Thomas Cech, Mary Coe, Pamela Craig, and Thomas Glocer.

Merck & Co., Inc. is a global healthcare company that provides prescription medicines, vaccines, biologic therapies, and animal health products. As of March 2025, it reported net sales of $15.6 billion and a market cap of approximately $278.9 billion.

As of Jun 18, Merck & Co., Inc. has a market capitalization of $278.9 billion, with net sales of $63.8 billion and net profit of $17.5 billion over the latest four quarters.